Admedus" CardioCell biomaterial scaffold technology validated by independent peer-reviewed study - Proactive Investors Australia

Admedus" CardioCell biomaterial scaffold technology validated by independent peer-reviewed study  Proactive Investors Australia

Admedus Ltd (ASX:AHZ) has had its CardioCel transcatheter aortic valve replacement (TAVR) devices validated through the publication of an independent study ...



Comments

Popular posts from this blog

Internal vs. Family Medicine: Who's Who in Primary Care - Avera Health

Different types of doctors in South Africa and their salaries 2022 - Briefly

Ebstein's Anomaly: Symptoms, Causes, and Treatments - Verywell Health